JPRN-jRCT1051190122招募中3 期
Effect of Pemafibrate and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular Ultrasound - PRALINE study
Toh Ryuji0 个研究点目标入组 46 人开始时间: 2020年3月19日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 46
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients who satisfy all of the following inclusion criteria were enrolled in this study.
- •(1)Patients who underwent PCI with ACS (ST-elevated myocardial infarction, non-ST elevated myocardial infarction, unstable angina) or stable angina pectoris
- •ACS definition:
- •A) ST-elevated myocardial infarction
- •(1) Chest symptoms (chest pain, shortness of breath, etc.) suggestive of ischemia are observed.
- •(2) ST elevation of 1 mm or more in two or more successive chest leads or limb lead electrocardiograms, or new onset left bundle branch block was detected
- •(3) Increasing of blood test value suggesting myocardial necrosis (troponin T or troponin I is positive, or CPK is more than twice the upper limit of the reference value).
- •B) Non-ST elevated myocardial infarction
- •(1) Chest symptoms (chest pain, shortness of breath, etc.) suggestive of ischemia are observed.
- •(2) ST depression more than 0.5 mm, negative T wave (3 mm or more, or transient ST rise (0.5 mm or less) is detected.
- •(3) Increasing of blood test value suggesting myocardial necrosis (troponin T or troponin I is positive, or CPK is more than twice the upper limit of the reference value).
- •C) Unstable angina: It is defined as satisfying (1) and satisfying any one of (2) to (6).
- •(1) Chest symptoms (chest pain, shortness of breath, etc.) suggestive of ischemia are observed.
- •(2) ST depression of 0.5 mm or more, or T wave deformation of 3 mm or more is observed.
- •(3) Increasing of troponin T is observed.
- •(4) Confirm by diagnostic imaging of culprit lesions of ACS (CAG, MDCT, etc.).
- •(5) A new wall motion reduction is observed by echocardiography.
- •(6) There is reversible myocardial blood flow reduction induced by a drug, exercise load, or thallium scintigraphy.
- •D) sAP: sAP does not fall under any of the above, but satisfies one of the following (1) to (3).
- •(1) There are symptoms suggestive of ischemia.
- •(2) There is reversible myocardial blood flow reduction induced by a drug, exercise load, or thallium scintigraphy.
- •(3) There is significant stenosis in a coronary artery with image diagnosis (CAG, MDCT, etc.).
- •(2)Patient who received statin therapy before PCI or statin therapy started after PCI.
- •(3)At the time of PCI, 25 to 75% of non-treated lesions remained, patients with images of analyzable NIRS-IVUS and maxLCBI (4 mm)>100.
- •(4)Patients who had a fasting TG level of 150 mg/dl or higher or a non-fasting TG level of 175 mg/dl or higher before randomization.
- •(5)Patients with <100 mg/dl of LDL-C at the time of randomization.(<70 mg/dl of LDL-C for patients who have past history of ACS or with familial hypercholesterolemia, or diabetic patients who are complicated by noncardiogenic cerebral infarction, peripheral arterial disease, metabolic syndrome, multiple majo risk factors or smoking)
- •(6)Patients aged 20 years or older at the time of PCI.
- •(7)Patient who got written informed consent from himself or herself.
排除标准
- •Patients who satisfy any of the following exclusion criteria were excluded from this study.
- •(1) Patients who have been treated with fibrates before PCI.
- •(2) Patients had uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg) between the time of PCI and randomization visit.
- •(3) Patients who have a HbA1c level of 7.0 % or higher despite treatment.
- •(4) Patients who known hypersensitivity to pemafibrate or rosuvastatin.
- •(5) Patients with severe liver or renal dysfunction.
- •(6) Patients with any of the warnings, contraindications mentioned in the domestic package insert of rosuvastatin.
- •(7) Patients with any of the warnings, contraindications mentioned in the domestic package insert of pemafibrate.
- •(8) Pregnant or breast-feeding women.
- •(9) Patients recognized as inadequate by attending physician
研究者
相似试验
尚未招募
4 期
The effect of combination of rosuvastatin and fenofibrate and metoprolol on the coronary atheroma plaque progression detected by multi-detector spiral computed tomographycoronary artery diseaseCardiovascular - Coronary heart diseaseMetabolic and Endocrine - Other metabolic disordershyperlipidemiaACTRN12611000394943Peking University Health Science Center520
已完成
不适用
Comparison of Effects of Pitavastatin and Rosuvastatin on Patients With Chronic Heart Failureheart failureJPRN-UMIN000007695Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine30
已完成
3 期
Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed DyslipidemiaMixed DyslipidemiasNCT02262143IlDong Pharmaceutical Co Ltd362
招募中
不适用
Comparison between the effect of Rosuvastatin and Orlept (Sodium Valproate) in Decrease of migraine headachesMigraine headaches.MigraineIRCT20180114038369N1Ghoum University of Medical Sciences40
招募中
2 期
effect of atorvastatin and rosuvastatin in acute ischemic stroke patientsAcute ischemic stroke.Cerebral infarctionIRCT20181009041286N2Kashan University of Medical Sciences40